Skip to main content

Advertisement

Table 5 Summary of published studies of SBRT-treated centrally located lung tumors

From: Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry

Author # Patients Lesion Type Dose/fraction (Fx) Median Follow-up (months) Local Control (years) Overall Survival (years)
Timmerman [10] 70 T1-T2,N0M0 NSCLC 60-66 Gy/3 Fx 17.5 2-yr: 95 % 2-yr: 54.7 %
Milano [13] 53 Primary, Metastases 30-63 Gy/2.5-5 Fx 10 2-yr: 73 % 2-yr:
Stage I: 72 %
Stage II-III:12 %
Mets: 49 %
Song [9] 32 Stage I NSCLC 40-60 Gy/3-4 Fx 26.5 2-yr: 85.3 % 1-yr: 70.9 %
2-yr: 38.5 %
Unger [18] 20 Hilar lesions -Primary, Metastases 30-40 Gy/5 Fx 10 1-yr: 63 % 1-yr: 54 %
Haasbeek [12] 63 Stage I-II NSCLC 60 Gy/8 Fx 35 2-yr: 92.6 % 2-yr: 69 %
5-yr: 92.6 % 5-yr: 49.5 %
Rowe [16] 47 Primary, Metastases BED10: 60–151.2/3-5 Fx 11.3 2-yr: 94 % NA
BED ≥ 100 Gy: 100 %
BED < 100 Gy: 80 %
Nuyttens [14] 56 Primary, Metastases 45-60 Gy/5-6 Fx 23 2-yr: 76 % 2-yr: 60 %
BED > 100: 85 % 3-yr: 53 %
BED ≤ 100: 60 %
Chang [11] 100 Primary, isolated recurrences 50 Gy/4 Fx 30.6 3-yr: 96.5 % 3-yr: 70.5 %
70 Gy/5 Fx
Bahig [19] 39 T1-T2N0 NSCLC Median BED10: 113 Gy (range 106–180 Gy) 22 2-yr: 89 % 2 yr: 74 %
Schanne [17] 90 Stage I/II 24 – 60 Gy/1-18 Fx 18.8 1-yr: 76 % 1-yr: 72 %
2-yr: 64 % 3-yr: 29 %
3-yr: 52 %
Current study 111 T1-T2 NSCLC, Metastases 20 – 60 Gy/1-5 Fx 17 1-yr: 89 % 2-yr:
2-yr: 72 % T1: 79 %
T2: 32.1 %
Mets: 49.6 %